Oculis Holding AG Ordinary shares (OCS)
Stock · NASDAQ · Health Care
$7.29as of 10/16/2026
Price chart
Active signals
OCS Signal Track Record
How signals performed across all stocks →What OCS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | +0.3% | 55% | September 30, 2026 |
| Bollinger Band Breakout | 25 | +0.3% | 56% | June 30, 2026 |
| 200-Day Moving Average TouchActive now | 21 | +1.4% | 81% | December 2, 2025 |
| Bollinger Band Breakdown | 18 | -2.1% | 39% | September 9, 2026 |
| Any 20-session window (baseline) | +0.5% | 59% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 60
- Website
- oculis.com/
Fundamentals
- 1-day range
- $7.15$7.6
- Market cap
- $717.85M
- P/E (trailing)
- —
- P/E (forward)
- -3.82
- EPS (trailing)
- $-1.39
- Dividend yield
- —
- Beta
- 0.29
- Avg. volume
- 259.9K
Forecasts
10 analyst ratings
Oculis Holding AG Ordinary shares Competitors
Chosen by industry and closest market cap.
- OCSOculis Holding AG Ordinary shares$7.29▼ 1.49%Market cap $717.85MP/E —$7.11$34.48
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- RIGLRigel Pharmaceuticals Inc. Common Stock$45.97▼ 2.71%Market cap $732.62MP/E 2.76$24.95$52.24
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
- CTMXCytomX Therapeutics Inc. Common Stock$2.28▼ 5.39%Market cap $733.66MP/E —$2.2$8.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OCS Oculis Holding AG Ordinary shares | $717.85M | — | $7.29 | ▼ 1.49% | $7.11$34.48 |
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| RIGL Rigel Pharmaceuticals Inc. Common Stock | $732.62M | 2.76 | $45.97 | ▼ 2.71% | $24.95$52.24 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
| CTMX CytomX Therapeutics Inc. Common Stock | $733.66M | — | $2.28 | ▼ 5.39% | $2.2$8.21 |
P/E shows — for peers not currently carrying a live signal of their own.
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analysts See 200% Upside for Oculis (OCS) from Current Levels
Wall Street analysts see significant upside potential for Oculis Holding AG, with consensus price targets suggesting the stock could rally substantially from recent levels. The company operates in the biotech/pharmaceutical space, where pipeline developments and clinical trial results often drive analyst sentiment. Current analyst average targets range notably above present trading levels, though individual analyst estimates vary. The stock has touched its support level multiple times recently, indicating established price boundaries.
Analysts See 200% Upside for Oculis (OCS) from Current Levels. Wall Street analysts see significant upside potential for Oculis Holding AG, with consensus price targets suggesting the stock could rally substantially from recent levels. The company operates in the biotech/pharmaceutical space, where pipeline developments and clinical trial results often drive analyst sentiment. Current analyst average targets range notably above present trading levels, though individual analyst estimates vary. The stock has touched its support level multiple times recently, indicating established price boundaries.